RxDoctor Payments Data

Keith Haynie

Psychiatric/Mental Health · Espanola, NMNPI 1033355284

Payments from drug & device makers

$705in general payments, 2019–2025

Across 48 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$243
  • AbbVie$193
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$86
  • Axsome Therapeutics, Inc.$80
  • Neurocrine Biosciences, Inc.$45
  • E.r. Squibb & Sons, L.L.C.$36
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$705 in reported general payments places this provider in the 70th percentile of 228 psychiatric/mental health providers in New Mexico.

See all psychiatric/mental health providers in New Mexico

Medicare billing

Part B allowed, 2024
$48,409
Medicare patients
101
Services billed
774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole13$17,910
Oxycodone Hcl79$2,212
Venlafaxine Hcl ErVenlafaxine Hcl47$1,213
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate19$1,067
Aripiprazole54$814
Methylphenidate Hcl26$729
Quetiapine Fumarate23$721
Bupropion XlBupropion Hcl42$694
Duloxetine Hcl42$657
Mirtazapine31$489
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$463
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine23$460
Memantine Hcl19$423
Buspirone Hcl48$405
Lamotrigine42$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$243$17,91013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 228 psychiatric/mental health providers in New Mexico.

Other psychiatric/mental health in Espanola

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →